The Life of Tempus Co-Founder Eric Lefkofsky

Tempus is a technology company that is working to use modern technology in the fight against disease. Co-founded by Eric Lefkofsky, this is a company that is hoping to use the data that is gained from one patient to help the next patient. This company is one that understands the advancements that are being made and that uses them in the work that they do. Tempus has a mission to change the way that clinical data is used. They would like to provide physicians with the kind of help that they need to better treat the patients who come to see them and learn more about Eric.

Eric Lefkofsky is the son of a structural engineer father and a schoolteacher mother, and he graduated from Southfield-Lathrup High School in 1987. After receiving his high school education, he went on to study at the University of Michigan. He graduated from the University of Michigan in 1991, with honors. Following the schooling that he received at the University of Michigan, he went on to continue his education. Eager to learn more, he studied at the University of Michigan Law School. Through attending the law school, he received his Juris Doctor in 1993 and more information click here.

Giving is something that Eric Lefkofsky is passionate about, and he and his wife founded the Lefkofsky Foundation together to help those who need their assistance. This trust fund is something that was put together to be of support to a variety of causes around the world, with a focus on children. In addition to the foundation that he formed with his wife, Eric Lefkofsky also joined The Giving Pledge in 2013. This campaign is a helpful one that allows wealthy individuals like him to help others. He has given much of his money to the good of others in hopes of helping those in need.

More Visit:

Seattle Genetics role in evolving Cancer Treatment Technologies

Seattle Genetics is an internationally recognized company that has specialized in developing targeted cancer cures. The firm’s founder is called Clay Siegall, and he has been its chairman for the past two decades that it has been in business. Seattle Genetics has impacted the pharmaceuticals industry positively by making inventions that have transformed cancer treatment. The biotechnology firm was the first to develop a technology that is called antibody-drug conjugates (ADCs). This formula has been used in manufacturing effective cancer drugs that have less harm to patients compared to chemotherapies.

Siegall has led the company and its technicians in using the ADC technology to develop drugs such as GlaxoSmithKline, Pfizer, AbbVie, and Roche. It has managed to get FDA-approval for these cures, and has commercialized them in the United States and overseas. Clay has served as a biotechnology researcher for the past three decades. Before founding Seattle Genetics, he served organizations such as the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. Siegall’s expertise also enabled him to be appointed to the boards of companies such as BioPharmaceuticals, Ultragenyx, and Mirna Therapeutics. He holds bachelor’s degree and a Ph.D. in zoology and genetics respectively.

The research work of Seattle Genetic has significantly improved cancer treatment across the world. Its success has facilitated the growth of Clay Siegall’s career and also earned him a lot of respect in the pharmaceuticals industry. In 2013, the researcher was appointed by Mirna Therapeutics to act as its external board member. He served as an advisor to the company on matters that dealt with the development of therapeutics that are based on micro-RNA. Siegall has invented several new products at Seattle Genetics, and he has 15 patents. The researcher has also published a couple of biotechnology-based books.

The commercialization of ADC drugs has facilitated the growth of Seattle Genetics. Over 21 drugs have been manufactured by using the technology. The biotechnology firm as earned more than $675 as revenue from selling cancer medicines in the United States and abroad. It has mobilized its researchers to focus on developing personalized treatments for the life-threatening disease.